Last reviewed · How we verify
Reamberin® solution for infusion, 1.5 %
Reamberin® solution for infusion, 1.5 % is a Small molecule drug developed by POLYSAN Scientific & Technological Pharmaceutical Company. It is currently in Phase 2 development.
At a glance
| Generic name | Reamberin® solution for infusion, 1.5 % |
|---|---|
| Sponsor | POLYSAN Scientific & Technological Pharmaceutical Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old
- REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reamberin® solution for infusion, 1.5 % CI brief — competitive landscape report
- Reamberin® solution for infusion, 1.5 % updates RSS · CI watch RSS
- POLYSAN Scientific & Technological Pharmaceutical Company portfolio CI
Frequently asked questions about Reamberin® solution for infusion, 1.5 %
What is Reamberin® solution for infusion, 1.5 %?
Reamberin® solution for infusion, 1.5 % is a Small molecule drug developed by POLYSAN Scientific & Technological Pharmaceutical Company.
Who makes Reamberin® solution for infusion, 1.5 %?
Reamberin® solution for infusion, 1.5 % is developed by POLYSAN Scientific & Technological Pharmaceutical Company (see full POLYSAN Scientific & Technological Pharmaceutical Company pipeline at /company/polysan-scientific-technological-pharmaceutical-company).
What development phase is Reamberin® solution for infusion, 1.5 % in?
Reamberin® solution for infusion, 1.5 % is in Phase 2.